HOXA-AS2 promotes type I endometrial carcinoma via miRNA-302c-3p-mediated regulation of ZFX

• Published in: Cancer cell international Vol. 20; no. 1; p. 359
• Main Authors: Song, Ning, Zhang, Ying, Kong, Fanfei, Yang, Hui, Ma, Xiaoxin
• Format: Journal Article
• Language: English
• Published: England BioMed Central 31-07-2020; BMC
• Subjects: Antisense RNA; Apoptosis; Cancer therapies; Carcinoma; Cell adhesion & migration; Cell cycle; Cell migration; Cell proliferation; Chitinase; Cholecystokinin; Endometrial cancer; Endometrial carcinoma; Endometrium; Fluorides; Gene expression; HOXA-AS2; Leukemia; Medical prognosis; Membranes; Metastasis; MicroRNAs; miRNA; MiRNA-302c-3p; Non-coding RNA; Plasmids; Primary Research; Proteins; Roles; Tumors; Uterine cancer; Western blotting; YKL-40; ZFX; Zinc finger proteins; China; MiRNA-302c-3p; YKL-40; Endometrial carcinoma; ZFX; HOXA-AS2
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-020-01443-0

HOXA cluster antisense RNA2 (HOXA-AS2), a long-chain non-coding RNA, plays an important role in the behavior of various malignant tumors. The roles of HOXA-AS2 in endometrial cancer remain unclear.
We test expression levels of HOXA-AS2, miRNA-302c-3p, the transcription factor zinc finger X-chromosomal protein (ZFX), and the chitinase-like protein YKL-40 in endometrial carcinoma by qRT-PCR and western blotting. Luciferase reporter and qRT-PCR assays were conducted to identify potential binding sites of HOXA-AS2 to miRNA-302c-3p. Cell cycle, migration and invasion ability of endometrial cancer cells were investigated using flow-cytometric analysis, CCK-8 and transwell assays, respectively.
HOXA-AS2 levels were significantly increased in endometrial cancer specimens compared to normal endometrial specimens. Upregulated HOXA-AS2 promoted invasion and proliferation of type I endometrial cancer cells. HOXA-AS2 silenced miRNA-302c-3p by binding to it. MiRNA-302c-3p negatively regulates ZFX and YKL-40. Thus HOXA-AS2 promotes the development of type I endometrial cancer via miRNA-302c-3p-mediated regulation of ZFX.
These findings suggest that HOXA-AS2 can act as a new therapeutic target for type I endometrial cancer.